🔗 Share this article World Health Organization Sounds Warning Over Severe Lack of Obesity Medications Less than a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the World Health Organization as it issues its initial guidance on the medications. Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs. Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major obstacles to widespread availability to the jabs that can assist patients in reducing substantial body mass, says the organization. Skinny Jab Supply Crisis Even in the current most favorable outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of those who need them, according to the health organization. The advice urges countries and companies to increase availability, via strategies including patent sharing. The intellectual property rights on semaglutide – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function These medications replicate a natural hormone to delay gastric emptying, curb appetite and enhance satiety so people reduce food intake. Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs. Research suggests people may put most of the weight back on within a year of discontinuing the medication, as their normal hunger resume. To be above a healthy weight increases your chance for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
Less than a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the World Health Organization as it issues its initial guidance on the medications. Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs. Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major obstacles to widespread availability to the jabs that can assist patients in reducing substantial body mass, says the organization. Skinny Jab Supply Crisis Even in the current most favorable outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of those who need them, according to the health organization. The advice urges countries and companies to increase availability, via strategies including patent sharing. The intellectual property rights on semaglutide – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function These medications replicate a natural hormone to delay gastric emptying, curb appetite and enhance satiety so people reduce food intake. Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs. Research suggests people may put most of the weight back on within a year of discontinuing the medication, as their normal hunger resume. To be above a healthy weight increases your chance for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.